Holly B. Kordasiewicz, Ph.D. - Publications

2006 University of Minnesota, Twin Cities, Minneapolis, MN 
Neuroscience Biology

11/44 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Skotte NH, Southwell AL, Østergaard ME, Carroll JB, Warby SC, Doty CN, Petoukhov E, Vaid K, Kordasiewicz H, Watt AT, Freier SM, Hung G, Seth PP, Bennett CF, Swayze EE, et al. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. Plos One. 9: e107434. PMID 25207939 DOI: 10.1371/Journal.Pone.0107434  0.44
2014 Southwell AL, Skotte NH, Kordasiewicz HB, Østergaard ME, Watt AT, Carroll JB, Doty CN, Villanueva EB, Petoukhov E, Vaid K, Xie Y, Freier SM, Swayze EE, Seth PP, Bennett CF, et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 2093-106. PMID 25101598 DOI: 10.1038/Mt.2014.153  0.44
2013 Arnold ES, Ling SC, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, Kordasiewicz HB, McAlonis-Downes M, Platoshyn O, Parone PA, Da Cruz S, Clutario KM, Swing D, Tessarollo L, Marsala M, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proceedings of the National Academy of Sciences of the United States of America. 110: E736-45. PMID 23382207 DOI: 10.1073/Pnas.1222809110  0.44
2012 Yu D, Pendergraff H, Liu J, Kordasiewicz HB, Cleveland DW, Swayze EE, Lima WF, Crooke ST, Prakash TP, Corey DR. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell. 150: 895-908. PMID 22939619 DOI: 10.1016/J.Cell.2012.08.002  0.44
2012 Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron. 74: 1031-44. PMID 22726834 DOI: 10.1016/J.Neuron.2012.05.009  0.44
2011 Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, Kordasiewicz H, Sedaghat Y, Donohue JP, Shiue L, Bennett CF, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nature Neuroscience. 14: 459-68. PMID 21358643 DOI: 10.1038/Nn.2779  0.44
2008 Miller TM, Smith RA, Kordasiewicz H, Kaspar BK. Gene-targeted therapies for the central nervous system. Archives of Neurology. 65: 447-51. PMID 18268183 DOI: 10.1001/Archneur.65.4.Nnr70007  0.44
2007 Boulware MI, Kordasiewicz H, Mermelstein PG. Caveolin proteins are essential for distinct effects of membrane estrogen receptors in neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 9941-50. PMID 17855608 DOI: 10.1523/Jneurosci.1647-07.2007  0.44
2007 Kordasiewicz HB, Gomez CM. Molecular pathogenesis of spinocerebellar ataxia type 6. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 4: 285-94. PMID 17395139 DOI: 10.1016/J.Nurt.2007.01.003  0.44
2007 Raike RS, Kordasiewicz HB, Thompson RM, Gomez CM. Dominant-negative suppression of Cav2.1 currents by alpha(1)2.1 truncations requires the conserved interaction domain for beta subunits. Molecular and Cellular Neurosciences. 34: 168-77. PMID 17161621 DOI: 10.1016/J.Mcn.2006.10.011  0.44
2006 Kordasiewicz HB, Thompson RM, Clark HB, Gomez CM. C-termini of P/Q-type Ca2+ channel alpha1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity. Human Molecular Genetics. 15: 1587-99. PMID 16595610 DOI: 10.1093/Hmg/Ddl080  0.44
Low-probability matches
2018 Friedrich J, Kordasiewicz HB, O'Callaghan B, Handler HP, Wagener C, Duvick L, Swayze EE, Rainwater O, Hofstra B, Benneyworth M, Nichols-Meade T, Yang P, Chen Z, Ortiz JP, Clark HB, et al. Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles. Jci Insight. 3. PMID 30385727 DOI: 10.1172/Jci.Insight.123193  0.16
2021 Zhao HT, John N, Delic V, Ikeda-Lee K, Kim A, Weihofen A, Swayze EE, Kordasiewicz HB, West AB, Volpicelli-Daley LA. Erratum: LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model. Molecular Therapy. Nucleic Acids. 24: 1051-1053. PMID 34141459 DOI: 10.1016/j.omtn.2021.05.013  0.01
2021 Cole TA, Zhao H, Collier TJ, Sandoval I, Sortwell CE, Steece-Collier K, Daley BF, Booms A, Lipton J, Welch M, Berman M, Jandreski L, Graham D, Weihofen A, Celano S, ... ... Kordasiewicz HB, et al. α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. Jci Insight. 6. PMID 33682798 DOI: 10.1172/jci.insight.135633  0.01
2020 Bennett CF, Kordasiewicz HB, Cleveland DW. Antisense Drugs Make Sense for Neurological Diseases. Annual Review of Pharmacology and Toxicology. PMID 33035446 DOI: 10.1146/annurev-pharmtox-010919-023738  0.01
2020 O'Callaghan B, Hofstra B, Handler HP, Kordasiewicz HB, Cole T, Duvick L, Friedrich J, Rainwater O, Yang P, Benneyworth M, Nichols-Meade T, Heal W, Ter Haar R, Henzler C, Orr HT. Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: A Safety Assessment. Molecular Therapy. Nucleic Acids. 21: 1006-1016. PMID 32818920 DOI: 10.1016/J.Omtn.2020.07.030  0.01
2020 Minikel EV, Zhao HT, Le J, O'Moore J, Pitstick R, Graffam S, Carlson GA, Kavanaugh MP, Kriz J, Kim JB, Ma J, Wille H, Aiken J, McKenzie D, Doh-Ura K, ... ... Kordasiewicz HB, et al. Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Research. PMID 32776089 DOI: 10.1093/Nar/Gkaa616  0.01
2020 Sullivan JM, Mazur C, Wolf DA, Horky L, Currier N, Fitzsimmons B, Hesterman J, Pauplis R, Haller S, Powers B, Tayefeh L, DeBrosse-Serra B, Hoppin J, Kordasiewicz H, Swayze EE, et al. Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system. Journal of Translational Medicine. 18: 309. PMID 32771027 DOI: 10.1186/S12967-020-02461-2  0.01
2020 Leavitt BR, Kordasiewicz HB, Schobel SA. Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks. Jama Neurology. PMID 32202594 DOI: 10.1001/Jamaneurol.2020.0299  0.01
2020 Poplawski SG, Garbett KA, McMahan RL, Kordasiewicz HB, Zhao H, Kennedy AJ, Goleva SB, Sanders TH, Motley ST, Swayze EE, Ecker DJ, Sweatt JD, Michael TP, Greer CB. An Antisense Oligonucleotide Leads to Suppressed Transcription of Hdac2 and Long-Term Memory Enhancement. Molecular Therapy. Nucleic Acids. 19: 1399-1412. PMID 32160709 DOI: 10.1016/J.Omtn.2020.01.027  0.01
2019 Reidenbach AG, Minikel EV, Zhao HT, Guzman SG, Leed AJ, Mesleh MF, Kordasiewicz HB, Schreiber SL, Vallabh SM. Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides. Biomolecules. 10. PMID 31861275 DOI: 10.3390/biom10010001  0.01
2019 Mazur C, Powers B, Zasadny K, Sullivan JM, Dimant H, Kamme F, Hesterman J, Matson J, Oestergaard M, Seaman M, Holt RW, Qutaish M, Polyak I, Coelho R, Gottumukkala V, ... ... Kordasiewicz H, et al. Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging. Jci Insight. 4. PMID 31619586 DOI: 10.1172/Jci.Insight.129240  0.01
2019 Raymond GJ, Zhao HT, Race B, Raymond LD, Williams K, Swayze EE, Graffam S, Le J, Caron T, Stathopoulos J, O'Keefe R, Lubke LL, Reidenbach AG, Kraus A, Schreiber SL, ... ... Kordasiewicz H, et al. Antisense oligonucleotides extend survival of prion-infected mice. Jci Insight. 5. PMID 31361599 DOI: 10.1172/Jci.Insight.131175  0.01
2019 Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, et al. Targeting Huntingtin Expression in Patients with Huntington's Disease. The New England Journal of Medicine. PMID 31059641 DOI: 10.1056/Nejmoa1900907  0.01
2018 Self WK, Schoch KM, Alex J, Barthélemy N, Bollinger JG, Sato C, Cole T, Kordasiewicz HB, Swayze E, Bateman RJ, Miller TM. Protein production is an early biomarker for RNA-targeted therapies. Annals of Clinical and Translational Neurology. 5: 1492-1504. PMID 30564616 DOI: 10.1002/Acn3.657  0.01
2018 Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, Caron NS, Østergaard ME, Anderson LM, Xie Y, Cengio LD, Findlay-Black H, Doty CN, Fitsimmons B, Swayze EE, et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease. Science Translational Medicine. 10. PMID 30282695 DOI: 10.1126/Scitranslmed.Aar3959  0.01
2018 McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, Schoch KM, Hoye ML, Shabsovich M, Sun L, Luo Y, Zhang M, Thankamony S, Salzman DW, Cudkowicz M, ... ... Kordasiewicz HB, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. The Journal of Clinical Investigation. PMID 30010620 DOI: 10.1172/Jci99081  0.01
2018 McLoughlin HS, Moore LR, Chopra R, Komlo R, McKenzie M, Blumenstein KG, Zhao H, Kordasiewicz HB, Shakkottai VG, Paulson HL. Oligonucleotide therapy mitigates disease in Spinocerebellar Ataxia Type 3 mice. Annals of Neurology. PMID 29908063 DOI: 10.1002/Ana.25264  0.01
2018 Lane RM, Smith A, Baumann T, Gleichmann M, Norris D, Bennett CF, Kordasiewicz H. Translating Antisense Technology into a Treatment for Huntington's Disease. Methods in Molecular Biology (Clifton, N.J.). 1780: 497-523. PMID 29856033 DOI: 10.1007/978-1-4939-7825-0_23  0.01
2018 Leavitt BR, Schobel SA, Kordasiewicz H. J03 Partial lowering of total huntingtin levels to treat adults with huntington’s disease (hd): potential benefits and theoretical risks from human studies and animal models Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.263  0.01
2018 Tabrizi SJ, Leavitt B, Landwehrmeyer B, Wild E, Saft C, Barker R, Craufurd D, Rickards H, Rosser A, Priller J, Kordasiewicz H, Czech C, Swayze E, Norris DA, Baumann T, et al. J01 Effects of IONIS-HTTRX (RG6042) in patients with early huntington’s disease, results of the first htt-lowering drug trial Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.261  0.01
2017 Zhao HT, Damle S, Ikeda-Lee K, Kuntz S, Li J, Mohan A, Kim A, Hung G, Scheideler MA, Scherer SS, Svaren J, Swayze EE, Kordasiewicz HB. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. The Journal of Clinical Investigation. PMID 29202483 DOI: 10.1172/Jci96499  0.01
2017 Luo X, Fitzsimmons B, Mohan A, Zhang L, Terrando N, Kordasiewicz H, Ji RR. Intrathecal administration of antisense oligonucleotide against p38α but not p38β MAP kinase isoform reduces neuropathic and postoperative pain and TLR4-induced pain in male mice. Brain, Behavior, and Immunity. PMID 29128611 DOI: 10.1016/J.Bbi.2017.11.007  0.01
2017 Mohan A, Fitzsimmons B, Zhao HT, Jiang Y, Mazur C, Swayze EE, Kordasiewicz HB. Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain. Pain. PMID 28976422 DOI: 10.1097/J.Pain.0000000000001074  0.01
2017 Zhao HT, John N, Delic V, Ikeda-Lee K, Kim A, Weihofen A, Swayze EE, Kordasiewicz HB, West AB, Volpicelli-Daley LA. LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model. Molecular Therapy. Nucleic Acids. 8: 508-519. PMID 28918051 DOI: 10.1016/J.Omtn.2017.08.002  0.01
2017 Moore LR, Rajpal G, Dillingham IT, Qutob M, Blumenstein KG, Gattis D, Hung G, Kordasiewicz HB, Paulson HL, McLoughlin HS. Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models. Molecular Therapy. Nucleic Acids. 7: 200-210. PMID 28624196 DOI: 10.1016/J.Omtn.2017.04.005  0.01
2017 Coffey SR, Bragg RM, Minnig S, Ament SA, Cantle JP, Glickenhaus A, Shelnut D, Carrillo JM, Shuttleworth DD, Rodier JA, Noguchi K, Bennett CF, Price ND, Kordasiewicz HB, Carroll JB. Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntington's disease. Plos One. 12: e0175968. PMID 28453524 DOI: 10.1371/Journal.Pone.0175968  0.01
2017 Hoye ML, Koval ED, Wegener AJ, Hyman TS, Yang C, O'Brien DR, Miller RL, Cole T, Schoch KM, Shen T, Kunikata T, Richard JP, Gutmann DH, Maragakis NJ, Kordasiewicz HB, et al. microRNA profiling reveals marker of motor neuron disease in ALS models. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 28416596 DOI: 10.1523/Jneurosci.3582-16.2017  0.01
2017 DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, Chen G, Shen T, Tran H, Nichols B, Zanardi TA, Kordasiewicz HB, Swayze EE, Bennett CF, Diamond MI, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Science Translational Medicine. 9. PMID 28123067 DOI: 10.1126/Scitranslmed.Aag0481  0.01
2017 Southwell AL, Skotte NH, Villanueva EB, Østergaard ME, Gu X, Kordasiewicz HB, Kay C, Cheung D, Xie Y, Waltl S, Dal Cengio L, Findlay-Black H, Doty CN, Petoukhov E, Iworima D, et al. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Human Molecular Genetics. PMID 28104789 DOI: 10.1093/Hmg/Ddx021  0.01
2017 Lane RM, Kordasiewicz HB, Smith A, Mignon L, Miller TM, Mummery CJ, Andreasen N, Narayanan P, Swayze E, Norris DA, Fitzsimmons B, Bennett CF. [O2-17-02]: DISCOVERY AND EARLY CLINICAL DEVELOPMENT OF IONIS-MAPTRX , THE FIRST TAU-LOWERING ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH MILD AD Alzheimer's & Dementia. 13: P600-P600. DOI: 10.1016/J.Jalz.2017.07.242  0.01
2016 Kennedy AJ, Rahn EJ, Paulukaitis BS, Savell KE, Kordasiewicz HB, Wang J, Lewis JW, Posey J, Strange SK, Guzman-Karlsson MC, Phillips SE, Decker K, Motley ST, Swayze EE, Ecker DJ, et al. Tcf4 Regulates Synaptic Plasticity, DNA Methylation, and Memory Function. Cell Reports. PMID 27568567 DOI: 10.1016/J.Celrep.2016.08.004  0.01
2016 Fitzsimmons B, Kordasiewicz H, Mazur C, Rigo F, Wancewicz E, Swayze E. (423) Distribution and efficacy of centrally and systemically administered antisense oligonucleotides in the pain system The Journal of Pain. 17: S80. DOI: 10.1016/j.jpain.2016.01.400  0.01
2015 Keiser MS, Kordasiewicz H, McBride J. Gene Suppression Strategies for Dominantly Inherited Neurodegenerative Diseases: lessons from Huntington's Disease and Spinocerebellar Ataxia. Human Molecular Genetics. PMID 26503961 DOI: 10.1093/hmg/ddv442  0.01
Hide low-probability matches.